We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The patient was presented at our institution's tumor board and the consensus was to proceed with palliative chemotherapy with gemcitabine/ carboplatin. It was felt that there is no role for radiation therapy at this time.
CT staging scans revealed clear chest except for granulomatous disease, multiple enlarged retroperitoneal aortocaval and paracaval lymph nodes as well as multiple bilobar metastatic lesions.
She initiated palliative chemotherapy with gemcitabine and carboplatin and tolerated well with no significant cytopenias or other untoward side effects.
jerrold tomlin
Nov 09, 2014
Why no sunitinib.?
Brad Somer
Nov 24, 2014
Collecting duct carcinomas have a much more aggressive behavior than clear cell carcinoma. They are typically more biologically similar to transitional cell carcinoma of the renal pelvis. There are case reports of VEGF-TKIs but most experience is with chemotherapy and in a review on collecting duct tumors in Current Oncology, 20 (3), 2013, Dason et al there was 26% response rate with Gem+platinum agent.
dalila amokrane
Dec 31, 2014
we use gemcitabine +platinum agent but no response was observed in 5 patients
Apr 25, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Manjari
Pandey
MD
Manjari Pandey MD
Nov 04, 2014
jerrold tomlin
Nov 09, 2014
Brad Somer
Nov 24, 2014
dalila amokrane
Dec 31, 2014
Apr 25, 2024
Pending Moderator approval.